Woronoff-Lemsi MC - Search Results

1

Infliximab continuation rates in patients with rheumatoid arthritis in everyday practice.

Wendling D, Materne GE, Michel F, Lohse A, Lehuede G, Toussirot E, Massol J, Woronoff-Lemsi MC. Wendling D, et al. Joint Bone Spine. 2005 Jul;72(4):309-12. doi: 10.1016/j.jbspin.2004.08.008. Epub 2004 Oct 30. Joint Bone Spine. 2005. PMID: 16038842

2

Impact of medical practices on the costs of management of rheumatoid arthritis by anti-TNFalpha biological therapy in France.

Fautrel B, Woronoff-Lemsi MC, Ethgen M, Fein E, Monnet P, Sibilia J, Wendling D. Fautrel B, et al. Joint Bone Spine. 2005 Dec;72(6):550-6. doi: 10.1016/j.jbspin.2004.12.009. Joint Bone Spine. 2005. PMID: 15996504

3

Predictive factors of tumour necrosis inhibitor treatment persistence for rheumatoid arthritis: An observational study in 8052 patients.

Fautrel B, Belhassen M, Hudry C, Woronoff-Lemsi MC, Levy-Bachelot L, Van Ganse E, Tubach F. Fautrel B, et al. Among authors: woronoff lemsi mc. Joint Bone Spine. 2020 May;87(3):267-269. doi: 10.1016/j.jbspin.2019.09.017. Epub 2019 Oct 11. Joint Bone Spine. 2020. PMID: 31606495 No abstract available.

4

Predictive factors of tumour necrosis inhibitor treatment persistence for rheumatoid arthritis: An observational study in 8052 patients.

Fautrel B, Belhassen M, Hudry C, Woronoff-Lemsi MC, Levy-Bachelot L, Van Ganse E, Tubach F. Fautrel B, et al. Among authors: woronoff lemsi mc. Joint Bone Spine. 2020 Mar;87(2):137-139. doi: 10.1016/j.jbspin.2019.10.004. Epub 2019 Oct 24. Joint Bone Spine. 2020. PMID: 31669808

5

From randomised clinical trials to clinical practice : a pragmatic cost-effectiveness analysis of Paclitaxel in first-line therapy for advanced ovarian cancer.

Limat S, Woronoff-Lemsi MC, Menat C, Madroszyk-Flandin A, Merrouche Y. Limat S, et al. Pharmacoeconomics. 2004;22(10):633-41. doi: 10.2165/00019053-200422100-00002. Pharmacoeconomics. 2004. PMID: 15244489

6

Induction-related cost of patients with acute myeloid leukaemia in France.

Nerich V, Lioure B, Rave M, Recher C, Pigneux A, Witz B, Escoffre-Barbe M, Moles MP, Jourdan E, Cahn JY, Woronoff-Lemsi MC. Nerich V, et al. Among authors: woronoff lemsi mc. Int J Clin Pharm. 2011 Apr;33(2):191-9. doi: 10.1007/s11096-010-9462-1. Epub 2011 Jan 28. Int J Clin Pharm. 2011. PMID: 21744189

7

Clinical and economic impact of epoetin in adjuvant-chemotherapy for breast cancer.

Fagnoni P, Limat S, Chaigneau L, Guardiola E, Briaud S, Schmitt B, Merrouche Y, Pivot X, Woronoff-Lemsi MC. Fagnoni P, et al. Support Care Cancer. 2006 Oct;14(10):1030-7. doi: 10.1007/s00520-006-0062-5. Epub 2006 Jun 27. Support Care Cancer. 2006. PMID: 16802128

8

[1/2 The anti-TNF alpha drugs].

Medjoub M, Limat S, Woronoff-Lemsi MC. Medjoub M, et al. Soins. 2007 Oct;(719):59-61. Soins. 2007. PMID: 18020248 French. No abstract available.

9

[Best practice drug therapy. B. Use of antibiotics 8/urinary infections].

Llamas-Prudhon C, Mandy B, Woronoff-Lemsi MC, Belon JP. Llamas-Prudhon C, et al. Soins. 2003 Apr;(674):53-4. Soins. 2003. PMID: 12725000 French. No abstract available.

10

Methodological validation of monitoring indicators of antibiotics use in hospitals.

Mandy B, Koutny E, Cornette C, Woronoff-Lemsi MC, Talon D. Mandy B, et al. Pharm World Sci. 2004 Apr;26(2):90-5. doi: 10.1023/b:phar.0000018595.78732.1c. Pharm World Sci. 2004. PMID: 15085943

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

115 results

Search Page

Filters